Following the promising results of the CENTAUR trial, Amylyx Pharmaceuticals has announced a plan to seek FDA approval for the drug AMX0035 for the treatment of ALS.
Merit Cudkowicz, MD
Merit Cudkowicz, MD
Chief, Neurology Department
Director, Sean M. Healey & AMG Center for ALS
Julieanne Dorn Professor of Neurology, Harvard Medical School
Departments, Centers, & Programs:
15 Parkman Street
Boston, MA 02114-3117
Sean M. Healey & AMG Center for ALS at Mass General
165 Cambridge Street Suite 600
Boston, MA 02115
- MD, Harvard Medical School/ BWH
- BS, Massachusetts General Hospital
- Residency, Massachusetts General Hospital
- Fellowship, Massachusetts General Hospital
American Board Certifications
- Neurology, American Board of Psychiatry and Neurology
Accepted Insurance Plans
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
My research activities are dedicated to the study and treatment of patients with Amyotrophic Lateral Sclerosis (ALS) and other neurological disorders. As Director of the MGH Neurological Clinical Research Institute and the Principal Investigator for the NINDS supported NeuroNEXT Clinical Coordinating center (www.neuronext.org), I design clinical trials to evaluate the safety and effectiveness of therapies that have shown promise in preclinical studies. In ALS, I co-founded an international consortium to test novel therapies in ALS, the Northeast ALS (NEALS) consortium. The NEALS consortium consists of over 128 clinical sites in the United States and Canada dedicated to performing joint academic led clinical trials in ALS.. We are leading several new trials in ALS. There is a critical need in neurology for highly trained clinical investigators who work collaboratively with basic scientists to develop new therapeutic strategies.
In 2018 we launched the Sean M. Healey & AMG Center for ALS at Mass General. This new Center is dedicated to accelerating therapy development and access to treatments for people with ALS. We are launching the first Platform Trial initiative in ALS where several treatments will be tested in one platform approach. This groundbreaking initiative will cut in half the time to develop treatments, increase by 67% ability of people to receive active treatment and cut costs of drug development by 33%. This approach, already successful in oncology, will revolutionize how treatments are developed in ALS. The Healey Center bring collaborators from around the world to work together to find treatments for people with ALS.
- Press Release
- Sep | 21 | 2021
Investigational drug SLS-005 (Trehalose) receives “May Proceed” notice and Central IRB approval for the HEALEY ALS Platform Trial
The Sean M. Healey & AMG Center for ALS at MGH received approval to proceed with adding SLS-005 (Trehalose) as an additional regimen in the HEALEY ALS Platform Trial.
- Nov | 8 | 2018
Massachusetts General Hospital (MGH) is teaming up with former NFL football player, children's book author and sports TV commentator, Tim Green, in an exciting new social media campaign aimed at knocking down barriers in amyotrophic lateral sclerosis (ALS) and bringing research to the next level.
- Jul | 29 | 2021
Dr. Cudkowciz recently spoke to the House Energy & Commerce Subcommittee on Health about the importance of expanded and accelerated access to new ALS drugs.
- Nov | 21 | 2019
Congratulations to Merit Cudkowicz, MD, MSc, Director of the Sean M. Healey and AMG Center for ALS and Chief of Neurology at Mass General, who presented “A Powerful Promise,” a keynote speech at Accelerating Transformation, the 2019 Press Ganey National Client & Executive Leadership Conference.
- Dec | 11 | 2019
The Healey Science Advisory Council (SAC) assembled on November 18th and 19th in Orlando, Florida to discuss several new science initiatives. This meeting also marks the one-year anniversary of the launch of the Sean M. Healey & AMG Center for ALS at Mass General.